Clinical and laboratory profile of urinary tract infections associated with extended spectrum-lactamase producing Escherichia coli and Klebsiella pneumoniae

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorAl Yousef S.A.
dc.contributor.authorYounis S.
dc.contributor.authorFarrag E.
dc.contributor.authorMoussa H.S.
dc.contributor.authorBayoumi F.S.
dc.contributor.authorAli A.M.
dc.contributor.otherDepartment of Medical Laboratory Technology
dc.contributor.otherCollege of Applied Medical Sciences
dc.contributor.otherUniversity of Hafr Al Batin
dc.contributor.otherHafr Al Batin
dc.contributor.otherSaudi Arabia; Faculty of Women for Art
dc.contributor.otherScience and Education
dc.contributor.otherAin Shams University
dc.contributor.otherEgypt; Microbiology Department
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherMSA University
dc.contributor.otherCairo
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:41:42Z
dc.date.available2020-01-09T20:41:42Z
dc.date.issued2016
dc.descriptionScopus
dc.description.abstractBackground. Urinary tract infection (UTI) is mainly due to invasion of the urethra, bladder or kidneys by pathogens. The emergence of extended spectrum �-lactamases (ESBL) is responsible for frequently observed empirical therapy failures. Objectives. To study the clinical and laboratory characteristics of UTIs caused by ESBL producing Escherichia coli (E. coli) and Klebsiella pneumonia (K. pneumonia). Methods. A cross-sectional clinical and laboratory study was performed at King Khalid Hospital, Hafr Al Batin, Saudi Arabia between March 2014 to October 2015. A total of 908 urine samples from suspected UTI patients was collected. Samples were isolated on Cysteine Electrolyte-Deficient (CLED) agar. Positive cultures were identified and tested for antimicrobial susceptibility by MicroScan WalkAway-96 SI System, and then ESBL was confirmed by double disc synergy test (DDST) and phenotypic confirmatory disc diffusion test (PCDDT). Results. A total of 680 samples (288 males and 392 females) were culture positive. 520 samples (76.5%)of E. Coli were found and 160 samples of K. pneumonia were identified (23.5%). ESBL testing showed 296 (218 E. coli and 78 K. pneumonia) samples of positive isolates. Non-ESBL isolates showed highest resistance to ampicillin followed by Mezocillin and Trimethoprim-Sulphamethoxazole- which are usually recommended as the initial treatment of UTI-while ESBL isolates showed resistance to third generation cephalosporin along with Ampicillin and Trimethoprim-Sulphamethoxazole. In this study, four significant risk factors for ESBL infection such as diabetes, recurrent UTI, previous use of antibiotics and previous hospitalization were found. Conclusion. Identifying the risk factors and antibiotic susceptibility patterns associated with ESBL producing E. coli and K. pneumonia is a useful guide for treatment strategy and control of ESBL UTI. 2016 by the Association of Clinical Scientists, Inc.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=26785&tip=sid&clean=0
dc.identifier.doihttps://doi.org/
dc.identifier.issn917370
dc.identifier.otherhttps://doi.org/
dc.identifier.urihttps://t.ly/KX8WB
dc.language.isoEnglishen_US
dc.publisherInternational Journal of Green Economics
dc.publisherAssociation of Clinical Scientistsen_US
dc.relation.ispartofseriesAnnals of Clinical and Laboratory Science
dc.relation.ispartofseries46
dc.subjectOctober University for Modern Sciences and Arts
dc.subjectجامعة أكتوبر للعلوم الحديثة والآداب
dc.subjectUniversity of Modern Sciences and Arts
dc.subjectMSA University
dc.subjectE . colien_US
dc.subjectESBLen_US
dc.subjectK. pneumoniaen_US
dc.subjectUTIen_US
dc.subjectamikacinen_US
dc.subjectamoxicillin plus clavulanic aciden_US
dc.subjectampicillinen_US
dc.subjectantibiotic agenten_US
dc.subjectcefazolinen_US
dc.subjectcefepimeen_US
dc.subjectcefotaximeen_US
dc.subjectcefoxitinen_US
dc.subjectcefpodoximeen_US
dc.subjectceftazidimeen_US
dc.subjectceftriaxoneen_US
dc.subjectcefuroximeen_US
dc.subjectcephalosporinen_US
dc.subjectciprofloxacinen_US
dc.subjectclavulanic aciden_US
dc.subjectcotrimoxazoleen_US
dc.subjectertapenemen_US
dc.subjectextended spectrum beta lactamaseen_US
dc.subjectfosfomycinen_US
dc.subjectgentamicinen_US
dc.subjectimipenemen_US
dc.subjectlevofloxacinen_US
dc.subjectmezlocillinen_US
dc.subjectpiperacillin plus tazobactamen_US
dc.subjecttobramycinen_US
dc.subjectbeta lactamaseen_US
dc.subjectadolescenten_US
dc.subjectadulten_US
dc.subjectagar mediumen_US
dc.subjectantibiotic sensitivityen_US
dc.subjectArticleen_US
dc.subjectbacterial growthen_US
dc.subjectbacterium identificationen_US
dc.subjectbacterium isolateen_US
dc.subjectchilden_US
dc.subjectcontrolled studyen_US
dc.subjectcross-sectional studyen_US
dc.subjectdiabetic patienten_US
dc.subjectdouble disc synergy testen_US
dc.subjectextended spectrum beta lactamase producing Escherichia colien_US
dc.subjectextended spectrum beta lactamase producing Klebsiella pneumoniaeen_US
dc.subjectfemaleen_US
dc.subjecthospitalizationen_US
dc.subjecthumanen_US
dc.subjectinhibition zoneen_US
dc.subjectlaboratory testen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmicrobiological examinationen_US
dc.subjectmicrobiology testen_US
dc.subjectminimum inhibitory concentrationen_US
dc.subjectnonhumanen_US
dc.subjectpriority journalen_US
dc.subjectrecurrent infectionen_US
dc.subjectrisk assessmenten_US
dc.subjectSaudi Arabiaen_US
dc.subjecturinary tract infectionen_US
dc.subjecturine samplingen_US
dc.subjectbiosynthesisen_US
dc.subjectclinical laboratory serviceen_US
dc.subjectdemographyen_US
dc.subjectenzymologyen_US
dc.subjectEscherichia colien_US
dc.subjectinfanten_US
dc.subjectisolation and purificationen_US
dc.subjectKlebsiella pneumoniaeen_US
dc.subjectmicrobial sensitivity testen_US
dc.subjectmicrobiologyen_US
dc.subjectmiddle ageden_US
dc.subjectpreschool childen_US
dc.subjecturinary tract infectionen_US
dc.subjectyoung adulten_US
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectbeta-Lactamasesen_US
dc.subjectChilden_US
dc.subjectChild, Preschoolen_US
dc.subjectClinical Laboratory Servicesen_US
dc.subjectDemographyen_US
dc.subjectEscherichia colien_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectInfanten_US
dc.subjectKlebsiella pneumoniaeen_US
dc.subjectMaleen_US
dc.subjectMicrobial Sensitivity Testsen_US
dc.subjectMiddle Ageden_US
dc.subjectUrinary Tract Infectionsen_US
dc.subjectYoung Adulten_US
dc.titleClinical and laboratory profile of urinary tract infections associated with extended spectrum-lactamase producing Escherichia coli and Klebsiella pneumoniaeen_US
dc.typeArticleen_US
dcterms.isReferencedByMarcus, N., Ashkenazi, S., Yaari, A., Samra, Z., Livni, G., Non-Escherichia coli versus Escherichia coli community-acquired urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and outcome (2005) The Pediatric infectious disease journal, 24 (7), pp. 581-585; Zorc, J.J., Kiddoo, D.A., Shaw, K.N., Diagnosis and management of pediatric urinary tract infections (2005) Clinical microbiology reviews, 18 (2), pp. 417-422; Kahlmeter, G., An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO� SENS Project (2003) Journal of Antimicrobial Chemotherapy, 51 (1), pp. 69-76; Piljic, D., Ahmetagic, S., Ljuca, F., Porobic, J.H., Clinical and laboratory characteristics of acute community-acquired urinary tract infections in adult hospitalised patients (2010) Bosnian journal of basic medical sciences/Udruzenjebasicnihmediciniskihznanosti= Association of Basic Medical Sciences, 10 (1), pp. 49-53; Gaspari, R.J., Dickson, E., Karlowsky, J., Doern, G., Antibiotic resistance trends in paediatricuropathogens (2005) International journal of antimicrobial agents, 26 (4), pp. 267-271; St�renburg, E., Mack, D., Extended-spectrum ?-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control (2003) Journal of infection, 47 (4), pp. 273-295; Kurtaran, B., Candevir, A., Tasova, Y., Kibar, F., Inal, A.S., Komur, S., Antibiotic resistance in community-acquired urinary tract infections: prevalence and risk factors (2010) Medical Science Monitor, 16 (5), pp. CR246-CR51; Sharma, I., Paul, D., Prevalence of community acquired urinary tract infections in silchar medical college, Assam, India and its antimicrobial susceptibility profile (2012) Indian journal of medical sciences, 66 (11), p. 273; Wikler, M.A., (2006) Performance standards for antimicrobial susceptibility testing: Sixteenth informational supplement, , Clinical and Laboratory Standards Institute; MacKenzie, F., Miller, C., Gould, I., Comparison of screening methods for TEM-and SHV-derived extended-spectrum ?-lactamase detection (2002) Clinical microbiology and infection, 8 (11), pp. 715-724; Kader, A.A., Kumar, A., Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiellapneumoniae in a general hospital (2005) Ann Saudi Med, 25 (3), pp. 239-242; Cockerill, F., (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, , Clinical and Laboratory Standards Institute; Kader, A.A., Angamuthu, K., Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiellapneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia (2005) Saudi medical journal, 26 (6), pp. 956-959; Kalantar, E., esmaeelMotlagh, M., Lornejad, H., Reshadmanesh, N., Prevalence of urinary tract pathogens and antimicrobial susceptibility patterns in children at hospitals in Iran (2008) Archives of Clinical Infectious Diseases, 3 (3); Assefa, A., Asrat, D., Woldeamanuel, Y., Abdella, A., Melesse, T., Bacterial profile and drug susceptibility pattern of urinary tract infection in pregnant women at TikurAnbessa Specialized Hospital Addis Ababa, Ethiopia (2008) Ethiopian medical journal, 46 (3), pp. 227-235; Chessbrough, M., (1993) Collection, transport and examination of specimens, , edical laboratory Manual for Wort-Heinemann Ltd, Oxford; Okonko, I., Ijandipe, L., Ilusanya, A., Donbraye-Emmanuel, O., Ejembi, J., Udeze, A., Detection of urinary tract infection (UTI) among pregnant women in Oluyoro Catholic Hospital, Ibadan, South-Western Nigeria (2010) Malaysian Journal of Microbiology, 6 (1), pp. 16-24; Shakibaie, M.R., Adeli, S., Salehi, M.H., Antimicrobial Susceptibility Pattern and ESBL Production among Uropathogenic Escherichia coli Isolated from UTI Children in Pediatric Unit of a Hospital in Kerman, Iran (2014) British Microbiology Research Journal, 4 (3), pp. 262-271; Khotayi, Q., Mamishi, S., Antibiotic resistance of germs isolated from urinary tract infections (2002) Iranian Journal of Pediatrics, 12 (2), pp. 28-32; Okonko, I.O., Soleye, F.A., Amusan, T.A., Ogun, A.A., Ogunnusi, T.A., Ejembi, J., Incidence of multi-drug resistance (MDR) organisms in Abeokuta, Southwestern Nigeria (2009) Global journal of pharmacology, 3 (2), pp. 69-80; Moyo, S.J., Aboud, S., Kasubi, M., Lyamuya, E.F., Maselle, S.Y., Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania (2010) BMC research notes, 3 (1), p. 348; Ahmed, A.A., Osman, H., Mansour, A.M., Musa, H.A., Ahmed, A.B., Karrar, Z., Antimicrobial agent resistance in bacterial isolates from patients with diarrhea and urinary tract infection in the Sudan (2000) The American journal of tropical medicine and hygiene, 63 (5), pp. 259-263; Azap, Arslan, H., Serefhanoglu, K., olakoglu, S., Erdogan, H., Timurkaynak, F., Risk factors for extended-spectrum ?-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections (2010) Clinical microbiology and infection, 16 (2), pp. 147-151; Siedelman, L., Kline, S., Duval, S., Risk factors for communityand health facility-acquired extended-spectrum ?-lactamase-producing bacterial infections in patients at the University of Minnesota Medical Center, Fairview (2012) American journal of infection control, 40 (9), pp. 849-853; Rahim, K.A.A.A., Mohamed, A.M.A., Prevalence of extended spectrum ?-lactamase-producing Klebsiellapneumoniae in clinical isolates (2014) Jundishapur journal of microbiology, 7 (11); Rodrigues, C., Joshi, P., Jani, S., Alphonse, M., Radhakrishnan, R., Mehta, A., Detection of-lactamases in nosocomial gram negative clinical isolates (2004) Indian journal of medical microbiology, 22 (4), p. 247; Hansotia, J.B., Agarwal, V., Pathak, A., Saoji, A., Extended spectrum beta-lactamase mediated resistance to third generation cephalosporins in Klebsiellapneumoniae in Nagpur, central India (1997) The Indian journal of medical research, 105, pp. 158-161; Song, W., Bae, I.K., Lee, Y.-N., Lee, C.-H., Lee, S.H., Jeong, S.H., Detection of extended-spectrum ?-lactamases by using boronic acid as an AmpC ?-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli (2007) Journal of clinical microbiology, 45 (4), pp. 1180-1184; Duttaroy, B., Mehta, S., Extended spectrum b lactamases (ESBL) in clinical isolates of Klebsiellapneumoniae and Escherichia coli (2005) Indian J PatholMicrobiol, 48 (1), pp. 45-48; Al Otaibi, F.E., Bukhari, E.E., Clinical and laboratory profiles of urinary tract infections caused by extended-spectrum betalactamase-producing Escherichia coli in a tertiary care center in central Saudi Arabia (2013) Saudi medical journal, 34 (2), pp. 171-176; Kandeel, A.Y., Prevalence and risk factors of extended-spectrum B-lactamases producing Enterobacteriaceae in a general hospital in Saudi Arabia (2014) Journal of Microbiology and Infectious Diseases, 4 (2); Kang, C.-I., Kim, S.-H., Kim, D.M., Park, W.B., Lee, K.-D., Kim, H.-B., Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiellapneumoniae (2004) Infection Control, 25 (10), pp. 860-867; Paterson, D.L., Ko, W.-C., Von Gottberg, A., Mohapatra, S., Casellas, J.M., Goossens, H., Antibiotic therapy for Klebsiellapneumoniae bacteremia: implications of production of extended-spectrum ?-lactamases (2004) Clinical Infectious Diseases, 39 (1), pp. 31-37; Ben-Ami, R., Rodrguez-Bao, J., Arslan, H., Pitout, J.D., Quentin, C., Calbo, E.S., A multinational survey of risk factors for infection with extended-spectrum ?-lactamase-producing Enterobacteriaceae in nonhospitalized patients (2009) Clinical Infectious Diseases, 49 (5), pp. 682-690
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download
Thumbnail Image
Name:
393.full.pdf
Size:
348.42 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Faculty Of Pharmacy Research Paper